Letter to the editor concerning the article: “Potential Cerebrovascular Accident Signal for Risankizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS)”

Ranjeeta Sinvhal; Whitney Krueger; Ryan Kilpatrick; Danielle Coppola

doi:10.22541/au.167808272.26909752/v1

loading page

Letter to the editor concerning the article: “Potential Cerebrovascular Accident Signal for Risankizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS)”

Ranjeeta Sinvhal,
Whitney Krueger,
Ryan Kilpatrick,
Danielle Coppola

01 Mar 2023Submitted to British Journal of Clinical Pharmacology

Show details

Hide details

06 Mar 2023Assigned to Editor

06 Mar 2023Submission Checks Completed

27 Mar 2023Reviewer(s) Assigned

01 Apr 2023Review(s) Completed, Editorial Evaluation Pending

03 Apr 2023Editorial Decision: Accept

Peer review status:ACCEPTED